Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX)

 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In.

Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX)

Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) on December 19, 2025, according to a report published in TheFly.

On December 17, 2025, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from Neutral to Overweight, with a price objective of $11 instead of $10. According to the firm, REC-4881 proved solid and long-lasting effectiveness in treating familial adenomatous polyposis.

The analyst informs investors in a research note that REC-4881’s addressable market is now larger than anticipated, providing explosive potential. JPMorgan has a 60% chance of success and peak revenues of more than $1 billion. Furthermore, per JPMorgan, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s CDK7 inhibitor REC-617 has proven early anti-tumor effectiveness in platinum-resistant ovarian cancer.

The company has reiterated its 2025 forecast with an expense base of less than $450 million, which does not include any inflows from partnerships. The overall forecast for 2026 has been maintained at less than $390 million. It is also anticipated that the cash position will sustain operations until the end of 2027 without the need for further funding.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology business.

While we acknowledge the risk and potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RXRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None